EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Drugging ERK1/2 in Cancer: A Glimpse of Small‐Molecule Inhibitors

Zhiqi Peng, Yuqi Fu, Yanmei Chen, Bo Fan, Bo Liu iD

Medicinal Research Reviews · 21.07.2026

DOI: 10.1002/med.70084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 21.07.2026. Verfasst von Zhiqi Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Precision Drug Innovation and Cancer Center, Second Affiliated Hospital of Dalian Medical University, Dalian, Chi…. Die Arbeit nennt 330 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province, Postdoctoral Research Fund of West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The extracellular signal‐regulated kinases 1 and 2 (ERK1/2) play central roles in the mitogen‐activated protein kinase (MAPK) pathway and have emerged as critical regulators of tumorigenesis. Aberrant ERK1/2 signaling is frequently observed in cancers such as melanoma, pancreatic cancer, and colorectal cancer. This review outlines the historical milestones in ERK1/2 research, from their discovery and structural characterization to their identification as oncogenic drivers and therapeutic targets. We detail the ERK1/2 signaling network, highlighting key upstream regulators, including rat sarcoma (RAS), rapidly accelerated fibrosarcoma (RAF), and mitogen‐activated protein kinase kinase (MEK), along with downstream substrates that mediate diverse oncogenic processes. Therapeutic approaches aimed at ERK1/2 currently fall into two main classes: small‐molecule inhibitors with single‐target specificity and those designed to simultaneously act on dual targets, along with combination therapies designed to overcome resistance and improve efficacy. Furthermore, we explore innovative approaches, including proteolysis‐targeting chimeras (PROTACs), autophagy‐targeting chimeras (AUTACs), and antibody‐drug conjugates (ADCs), which offer promising avenues for selectively modulating ERK1/2 activity. By integrating mechanistic insights with clinical development trends, this review underscores the potential of ERK1/2‐targeted therapies in precision oncology.

Schlagwörter

Stichwörter der Autor:innen

ERK1/2MAPK signaling pathwaycancer therapydrug discoverysmall‐molecule inhibitor

Autor:innen und Institutionen

  • Department of Urology, Institute of Precision Drug Innovation and Cancer Center, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Bo Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Sichuan Province
  • Postdoctoral Research Fund of West China Hospital, Sichuan University

Zitieren

APA

Peng, Z., Fu, Y., Chen, Y., Fan, B., & Liu, B. (2026). Drugging ERK1/2 in Cancer: A Glimpse of Small‐Molecule Inhibitors. Medicinal Research Reviews. https://doi.org/10.1002/med.70084

Vancouver

Peng Z, Fu Y, Chen Y, Fan B, Liu B. Drugging ERK1/2 in Cancer: A Glimpse of Small‐Molecule Inhibitors. Medicinal Research Reviews. 2026. doi:10.1002/med.70084

BibTeX
@article{Peng2026,
  author = {Peng, Zhiqi and Fu, Yuqi and Chen, Yanmei and Fan, Bo and Liu, Bo},
  title = {Drugging ERK1/2 in Cancer: A Glimpse of Small‐Molecule Inhibitors},
  journal = {Medicinal Research Reviews},
  year = {2026},
  doi = {10.1002/med.70084}
}
Kostenlos starten →